Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: strong gross margins and a solid cash position are positive, but increased operating expenses and widening net losses are concerning. The Q&A reveals positive early indications for new platforms, yet lacks detailed guidance, which may worry investors. The reduced revenue guidance, despite strong cash flow guidance, adds uncertainty. Overall, the mixed financial performance and cautious guidance suggest a neutral stock price movement.
Key Financial Performance
Revenue (Full Year 2025) $50.5 million, representing 86% year-over-year growth. The growth was driven by increased procedure volumes and surgeon adoption.
Revenue (Q4 2025) $15.2 million, representing 61% year-over-year growth. The growth was attributed to expansion in surgeon users and utilization rates.
Gross Margins (Full Year 2025) 75.3%, an increase from 73.8% in 2024. The improvement was due to lower contract manufacturing costs and internal efficiencies.
Gross Margins (Q4 2025) 76.5%, an increase from 74.7% in Q4 2024. The improvement was driven by supply chain productivity initiatives and reduced manufacturing costs.
Operating Expenses (Q4 2025) $20.9 million, up from $11.7 million in Q4 2024. The increase was due to higher personnel costs, sales headcount, and stock-based compensation.
Operating Expenses (Full Year 2025) $68.6 million, up from $44.2 million in 2024. The increase was driven by investments in R&D, sales, and administrative functions.
Net Loss (Q4 2025) $8.6 million, compared to $4.7 million in Q4 2024. The increase was due to higher operating expenses.
Net Loss (Full Year 2025) $29.6 million, compared to $24.3 million in 2024. The increase was attributed to higher operating expenses.
Adjusted EBITDA (Q4 2025) Negative $8.4 million, compared to negative $4.6 million in Q4 2024. The decline was due to increased operating expenses.
Adjusted EBITDA (Full Year 2025) Negative $28.4 million, compared to negative $23.7 million in 2024. The decline was due to increased operating expenses.
Cash and Investments (End of 2025) $109.9 million. This reflects a strong balance sheet position to support future growth.
Debt Facility (End of 2025) $15.6 million outstanding principal, with no additional draws planned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Aprevo Lumbar and Cervical Patient-Specific Interbody Portfolio: Advancements in digital production system reduced lead times to 6 business days. Two-year data showed a 74% reduction in reoperation rates for aprevo lumbar implants compared to conventional implants.
Myaprevo Ecosystem: Launched next-generation ecosystem integrating mobile and web-based applications for deeper integration with surgeons' workflows.
Corra Personalized Fixation Portfolio: Introduced corra cervical plates, fully personalized to patient anatomy, with a launch planned for the second half of 2026.
Surgeon Adoption: Added 101 new surgeon users in 2025, showcasing rapid clinical adoption.
Cervical Fusion Market: Launched aprevo cervical in December 2025, targeting patients with osteoporosis and osteopenia.
Production Efficiency: Reduced production lead times by 25%, achieving 6 business days for both cervical and lumbar products.
Integrated Manufacturing: Fully integrated manufacturing process for cervical and lumbar products on the same production line.
Bilateral Posterior Aprevo Procedure: Performed first-in-human procedure, with a launch planned for the second half of 2026.
Surgeon Education: Expanded medical education team and fully enrolled second annual Residents and Fellows Course.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The company relies on reimbursement codes and new technology add-on payments (NTAP) for its products. Any changes in reimbursement policies or delays in approvals could adversely impact financial performance.
Operational Scaling Risks: While the company has reduced production lead times to 6 business days, further scaling to meet growing demand could strain operational efficiency and supply chain management.
Financial Losses: The company reported a GAAP net loss of $29.6 million for 2025, an increase from $24.3 million in 2024. Continued losses could impact cash flow and financial stability.
Market Adoption Risks: Despite adding 101 new surgeon users, the adoption of new technologies like aprevo cervical and lumbar implants may face resistance from surgeons accustomed to traditional methods.
Economic and Competitive Pressures: The company operates in a competitive market for spine surgery solutions. Economic uncertainties or competitive pressures could impact market share and pricing strategies.
Dependence on Key Technologies: The company’s reliance on AI-driven personalized surgical plans and 3D-printed devices means any technological failures or delays in innovation could disrupt operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Expected revenue range is $70 million to $75 million, representing an annual growth of 44% at the midpoint of the range over the full year 2025.
Adjusted EBITDA Outlook: Anticipate continued improvement in adjusted EBITDA over the coming years, driven by revenue growth and increased operating leverage across the expense base.
Path to Cash Flow Breakeven: Expanding contribution margins enabled by the capital-light digital-first model are expected to support the path toward cash flow breakeven.
Product Launches in 2026: Launch of bilateral posterior aprevo procedure and corra cervical plating portfolio is planned for the second half of 2026.
Market Expansion: Focus on scaling personalized surgery business with reduced lead times and integrated manufacturing processes for cervical and lumbar products.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the two new indications or platforms announced this quarter, the bilateral approach and corra? How do they open up the market for you, and how are you thinking about investment in these while working on the cervical launch?
A:The bilateral aprevo lumbar is expected to accelerate adoption in the posterior surgery market, which constitutes about 8% of the lumbar fusion market. Early indications are positive. Corra represents the company's first move outside the disc space, adding personalization to the cervical plate. Both platforms are in early stages, with a full commercial launch expected in the back half of the year.
Q:What was the contribution of the cervical launch in the quarter, and how are you thinking about the ramp in 2026?
A:The cervical portfolio has seen positive responses from both surgeons and hospitals since its launch in December. The company anticipates continued ramp-up, especially with the addition of personalized corra plates, making it a significant part of the portfolio.
Q:What is the utilization of cervical among existing lumbar users?
A:About 10% of total users have been trained on cervical in a short period, showing strong traction in surgeon training and hospital approval processes.
Q:Can you explain the building blocks for the 2026 guidance, including new surgeon adds versus utilization growth?
A:The company is being prudent with guidance as a newly public entity. Early momentum in lumbar and cervical platforms, along with training programs, supports confidence in the guidance.
Q:How has the reduction in lead time impacted the business, particularly in terms of new surgeon adoption and reorders?
A:The reduction in lead time to 6 days has been significant, aiding new surgeon adoption and enabling the company to address emergent cases in trained surgeons' practices.
Q:What are your thoughts on ASP trends moving into 2026, and how does the cervical launch impact broader ASP?
A:Lumbar ASP remains stable, while cervical has a different reimbursement profile, leading to slightly lower overall ASP in 2026. The procedural mix will result in ASP in the mid- to high $20,000 range.
Q:Why is G&A running lower than expected, and what are your thoughts on operating expense growth in 2026?
A:G&A costs are expected to decline as a percentage of revenue due to fixed costs supporting a growing organization. The focus remains on R&D and sales/marketing investments to drive revenue growth, with operating leverage expected to improve.
Q:How has the reduced lead time impacted gross margin, and what are the expectations for margins in 2026?
A:The reduced lead time has improved manufacturing capacity and gross margins, which are expected to remain in the mid-70s range into 2026, supporting profitability.
Q:When should we expect a meaningful uptick in utilization within existing accounts?
A:The company is investing in surgeon education and training programs to support new users and drive incremental procedure volume utilization across the surgeon user base.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact contribution of the cervical launch in the quarter and the precise timeline for a meaningful uptick in utilization within existing accounts. Additionally, responses on 2026 guidance and ASP trends were somewhat general, lacking detailed numerical breakdowns.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI planning
Chairman
Chief
FDA
Full
NTAP
University
achievement
advancement
approach
area focus
bone
cervical
condition
corra plate
deformity
education
excellence
filing SEC
fixation
foundation surgery
fusion
highlight
human
implant
interbody
launch
osteoporosis osteopenia
outcome market
patient device
penetration
plating
procedure
production
quality
surgeon user
system
technology
NTNX Transcript
Nutanix, Inc. (NTNX) Presents at Bank of America 2026 Global Technology Conference Transcript
Neutral6-2
Nutanix, Inc. (NTNX) Q3 2026 Earnings Call Transcript
Positive5-28
The earnings call summary reveals a positive sentiment with strong bookings growth, optimistic revenue guidance, and strategic partnerships, particularly with AMD. Despite supply chain challenges, the company's guidance remains unchanged, indicating resilience. The Q&A section supports this with positive feedback on AI products and competitive positioning against VMware. However, the lack of specific guidance on deferred revenue and cash flow slightly tempers the outlook, but overall, the strategic initiatives and market opportunities suggest a positive stock price movement.
Nutanix, Inc. (NTNX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Neutral3-2
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents mixed signals: strong gross margins and a solid cash position are positive, but increased operating expenses and widening net losses are concerning. The Q&A reveals positive early indications for new platforms, yet lacks detailed guidance, which may worry investors. The reduced revenue guidance, despite strong cash flow guidance, adds uncertainty. Overall, the mixed financial performance and cautious guidance suggest a neutral stock price movement.
NTNX Slides
NTNX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
